Captain T Cell, a biotechnology start-up funded by the German Federal Ministry of Education and Research (BMBF) as part of the GO-Bio program, has successfully acquired seed funding amounting to 8.5 million euros. A consortium of life science investors, including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H, participated in the financing round.

The company, which specializes in the development of next-generation T-cell therapies, will use the capital to advance its research. The company is working on creating more effective and safer immunotherapies that support the body's own immune system in fighting cancer cells more efficiently. Among other things, the team uses the TCR-ALLO platform developed in-house. It is used for the off-the-shelf treatment of solid tumors. Captain T Cell was founded by a team of immuno-oncology experts of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and is based in Schönefeld/Berlin.

Dr. Felix Lorenz, CEO of Captain T Cell: This successful financing round allows us to accelerate our high-potential therapies and brings us closer to providing life-saving options for patients underserved by current treatments. We are steadfast in our mission to progress our lead candidate towards the clinic and to establish our TCR-ALLO platform as a leader in off-the-shelf solid tumor therapeutics."